Latest Content

FDA approves daraxonrasib, a first-in-class daily oral RAS inhibitor, doubling survival in metastatic pancreatic adenocarcinoma patients.

Emily Beard discusses how nurse navigators act as essential bridges, leveraging clinical intuition and time to address complex patient needs.

At the 29th APAO Symposium, Lifetime Achievement Award honoree Colleen Tetzlaff, PA-C, shared insights on adapting to rapid clinical advancements.

FDA approves two Ziihera combinations as a first-line treatment standard for adults with HER2-positive advanced gastroesophageal adenocarcinoma.

Kelsey Martin, APRN, discusses the tolerability and clinical benefits of frontline antibody-drug conjugates for metastatic TNBC.

Experts at the 2026 APAO Symposium highlighted patient education, clinical trial updates, and professional development in cancer care.

Kennon McCollum explains how psychosocial, physical, and financial barriers impact treatment selection for patients with CLL.

Learn how oncology nurses can leverage clinical strategies, baseline testing, and targeted referrals to optimize patient vitamin D during treatment.

Adding anti-obesity medication for survivors who do not respond early to lifestyle changes helps 42% achieve clinically meaningful weight loss.

A JAMA study of 73,042 veterans shows active surveillance for low-risk prostate cancer rose to 93%, with notable racial and social disparities.

How oncology nurses can dismantle patient myths, secure early dietitian referrals, and collaborate to optimize supportive care like vitamin D.

A JAMA Surgery study of 2.7M patients reveals decade-long increases in surgical delays, with significant racial and socioeconomic disparities.

Oncology clinical trial nurse navigator Elise Curry, RN, breaks down the key clinical questions surrounding the FDA approval of oral iberdomide.